MENU

Fox Chase Cancer Center News

Kimberly Berman, Valerie Heron, Nicolas Hoover, Carol Shellock, Christa Shine, Maureen Sims
June 24, 2022

Fox Chase East Norriton Nurses Receive 2022 Excellence in Nursing Award From Main Line Today

PHILADELPHIA (June 24, 2022)—Main Line Today has honored six Fox Chase Cancer Center – East Norriton nurses with their 2022 Excellence in Nursing Award. These exceptional professionals were nominated for their dedication and contributions throughout 2021. Fellow nurses from the region voted on the selections.

 

Sameer Patel, MD, FACS, chief of the Division of Plastic & Reconstructive Surgery at Fox Chase Cancer Center
June 24, 2022

Fox Chase Cancer Center’s Dr. Sameer Patel Inducted Into American Association of Plastic Surgeons

PHILADELPHIA (June 24, 2022)—Sameer Patel, MD, FACS, chief of the Division of Plastic & Reconstructive Surgery at Fox Chase Cancer Center, was recently inducted into the American Association of Plastic Surgeons (AAPS).

Erica Huelsmann, MD, a Gynecological Oncology Fellow at Fox Chase Cancer Center
June 21, 2022

Dr. Erica Huelsmann Wins a Conquer Cancer Annual Meeting Merit Award

PHILADELPHIA (June 21, 2022)—Erica Huelsmann, MD, a Gynecological Oncology Fellow at Fox Chase Cancer Center, has been awarded a 2022 Conquer Cancer Merit Award by Conquer Cancer, the ASCO Foundation. The prestigious award, given at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, supports researchers with projects that span many areas of cancer care, including precision medicine, palliative care, and breast cancer.

Daniel Geynisman, MD, the study author and chief of the Division of Genitourinary Medical Oncology at Fox Chase
June 1, 2022

Fox Chase Researchers Examine Racial Differences in Treatment and Outcomes of First-Line Therapies For Kidney Cancer

PHILADELPHIA (June 1, 2022)—African American/Black and white patients treated with similar first-line therapies for advanced kidney cancer experienced similar outcomes but different response rates, according to research from Fox Chase Cancer Center that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Michael J. Hall, MD, MS, lead author on the study and chair of the Department of Clinical Genetics at Fox Chase Cancer Center
June 1, 2022

Fox Chase Researchers Explore Ancestry-Specific Genetic Risk for Triple-Negative Breast Cancer

PHILADELPHIA (June 1, 2022)—Although women of African descent experience higher incidence and mortality from triple-negative breast cancer (TNBC) than women of other races or ethnicities, a recent study shows that the magnitudes of gene-specific risks of TNBC were similar across different racial/ethnic groups. Results from the study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

 Close-up of Siddharth Balachandran sitting at a desk, wearing a white coat and smiling
May 26, 2022

Fox Chase Researchers Rekindle Immunotherapy Responsiveness by Mimicking the Flu in Tumors

PHILADELPHIA (May 26, 2022)—In a study published in the prestigious journal Nature, Fox Chase Cancer Center researchers have shown that a drug candidate may help re-initiate immune responses by mimicking influenza virus infections in patients whose cancer is unresponsive to immunotherapy.

May 25, 2022

Dr. Laura Bukavina Wins a Urology Care Foundation Research Scholar Award

PHILADELPHIA (May 25, 2022)—Laura Bukavina, MD, MPH, a Urologic Oncology Fellow at Fox Chase Cancer Center, has been awarded a 2022 Urology Care Foundation Research Scholar Award, which supports future research leaders and ensures they receive the necessary training and guidance for a successful research career. The Urology Care Foundation is the official foundation of the American Urological Association (AUA).

A close-up shot of Roland Dunbrack, PhD with a grayish backdrop
May 10, 2022

Fox Chase Researchers Analyze Protein Structures to Aid in Designing Drugs Against Key Cancer Target

PHILADELPHIA (May 10, 2022)—In a study published today in the prestigious journal Cancer Research, Fox Chase Cancer Center researchers analyzed over 700 experimentally determined structures of the high-priority cancer targets KRAS, NRAS, and HRAS to facilitate drug discovery for these proteins.

Pages

Connect with Fox Chase